The development of dasatinib as a treatment for chronic myeloid leukemia (CML): From initial studies to application in newly diagnosed patients

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 12, 2013, Pages 1971-1984

  Hochhaus, Andreas ^a   Kantarjian, Hagop ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Early response; First line treatment; Second line treatment; Side effects

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL DISEASE; GENE MUTATION; HEADACHE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; LONG TERM CARE; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NEOADJUVANT THERAPY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES;

EID: 84888427778     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1488-z     Document Type: Review

References (122)

1. Apperley JF, Cortes JE, Kim DW et al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol 27:3472-3479
2. Baccarani M, Rosti G, Saglio G et al (2008) Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). [abstract 450]. Blood 112
3. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013 June 28 [Epub ahead of print]
4. Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114:5426-5435
5. Brave M, Goodman V, Kaminskas E et al (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14:352-359
6. Bristol-Myers Squibb (2013a) Open-label study evaluating dasatinib therapy discontinuation in patients with chronic phase chronic myeloid leukemia with stable complete molecular response (DASFREE). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://www.clinicaltrials.gov/ct2/show/ NCT01850004. Accessed 6 June 2013
7. Bristol-Myers Squibb (2013b) Phase IIb study of dasatinib versus imatinib in patients with CML-CP who have not achieved an early optimal response to imatinib (early switch). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01593254. Accessed 26 April 2013
8. Bristol-Myers Squibb (2013c) Studying first line treatment of chronic myeloid leukemia (CML) in a real-world setting (SIMPLICITY). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/ show/NCT01244750. Accessed 26 April 2013
9. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL (2005) Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102:3395-3400
10. Chang Q, Jorgensen C, Pawson T, Hedley DW (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99:1074-1082
11. Cortes J, Rousselot P, Kim DW et al (2007a) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213
12. Cortes J, Jabbour E, Kantarjian H et al (2007b) Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005-4011
13. Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176-2183
14. Cortes J, Talpaz M, Bixby D et al (2010a) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. [abstract 210]. Blood 116
15. Cortes JE, Jones D, O'Brien S et al (2010b) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398-404
16. Das J, Patmanabha R, Chen P et al (2005) Cyclic protein tyrosine kinase inhibitors. US patent number 006596746-B1. Patent issued July 22, 2003
17. Das J, Chen P, Norris D et al (2006) 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 49:6819-6832
18. de Lavallade H, Apperley JF, Khorashad JS et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363
19. Defina M, Ippoliti M, Gozzetti A et al (2012) Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. Cancer 118:5265-5269
20. Dewaele B, Floris G, Finalet-Ferreiro J et al (2010) Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 70:7304-7314
21. Donato NJ, Wu JY, Stapley G et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-698
22. Druker BJ, Guilhot F, O'Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417
23. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 38:218-220
24. ® (dasatinib) [summary of product characteristics]. Bristol-Myers Squibb Pharma EEIG, Uxbridge, UK
25. Fang JC, DeMarco T, Givertz MM et al (2012) World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult - a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 31:913-933
26. Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-2537
27. Guilhot F, Apperley J, Kim DW et al (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143-4150
28. Guilhot F, Kantarjian HM, Shah NP et al (2010) Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial. [abstract 2295]. Blood 116
29. Hanfstein B, Müller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096-2102
30. Hantschel O, Rix U, Schmidt U et al (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104:13283-13288
31. Hehlmann R, Hochhaus A, Baccarani M, European LeukemiaNet (2007) Chronic myeloid leukemia. Lancet 370:342-350
32. Hennigs JK, Keller G, Baumann HJ et al (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30
33. Hiwase DK, Saunders V, Hewett D et al (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14:3881-3888
34. Hiwase DK, White DL, Powell JA et al (2010) Blocking cytokine signalling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24:771-778
35. Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309
36. Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200-1206
37. Hochhaus A, O'Brien SG, Guilhot F et al (2009a) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061
38. Hochhaus A, Müller MC, Radich J et al (2009b) Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 23:1628-1633
39. Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC (2011) Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10:250-260
40. Hochhaus A, Shah NP, Cortes JE et al (2012a) Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. [abstract 6504]. J Clin Oncol 30
41. Hochhaus A, Boqué C, Bradley Garelik MB et al (2012b) Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib versus imatinib: DASISION 3-year follow-up. [abstract 0192]. Haematologica 97(s1):76
42. Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226-2238
43. Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432
44. Jabbour E, Kantarjian HM, Quintás-Cardama A et al (2011) Impact of dose reductions and interruptions due to adverse events (AEs) on efficacy in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) patients (pts) receiving either dasatinib (D) or imatinib (IM): analysis of the DASISION trial. [abstract 2768]. Blood 118
45. Kantarjian H, Pasquini R, Hamerschlak N et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143-5150
46. Kantarjian H, O'Brien S, Shan J et al (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837-845
47. Kantarjian HM, Pasquini R, Lévy V et al (2009a) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136-4147
48. Kantarjian H, Cortes J, Kim DW et al (2009b) Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322-6329
49. Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270
50. Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123-1129 (republished with permission of the American Society of Hematology, permission conveyed through Copyright Clearance Center, Inc.)
51. Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132
52. Khorashad JS, Milojkovic D, Mehta P et al (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111:2378-2381
53. Khoury HJ, Guilhot F, Hughes T, Kim DW, Cortes JE (2009) Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer 115:1381-1394
54. Khoury HJ, Cortes JE, Kantarjian H et al (2010) Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. [abstract 3421]. Blood 116
55. Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772-782
56. Kreutzman A, Ladell K, Koechel C et al (2011) Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587-1597
57. La Rosée P, Martiat P, Leitner A et al (2013) Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013 April 28 [Epub ahead of print]
58. Laneuville P, Baccarani M, Cortes JE et al (2011) Analysis of patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: management and outcomes. [abstract 6605]. J Clin Oncol 29
59. Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 7:e29828
60. Li J, Rix U, Fang B et al (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6:291-299
61. Lombardo LJ, Francis YL, Chen P et al (2004) Discover of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658-6661
62. Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437-4444
63. Marin D, Hedgley C, Clark RE et al (2012a) The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy. Blood 120:291-294
64. Marin D, Ibrahim AR, Lucas C et al (2012b) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232-238
65. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967-968
66. Mauro MJ, Baccarani M, Cervantes F et al (2008) Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). [abstract 7009]. J Clin Oncol 26
67. McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573-1619
68. Circulation 119:2250-2294
69. Montani D, Bergot E, Gunther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128-2137
70. Müller MC, Cortes JE, Kim DW et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944-4953
71. Mustjoki S, Rousselot P, Jalkanen S et al (2010) Dasatinib induces a rapid, dose-controllable mobilization of cytotoxic lymphocytes: a novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. [abstract 1204]. Blood 116
72. Mustjoki S, Richter J, Barbany G et al (2011) Favorable therapeutic responses in newly diagnosed CML-CP patients induced by dasatinib are reflected at the CD34+CD38+ progenitor cell but not at the CD34+CD38- stem cell level: results from randomized NordCML006 study. [abstract 784]. Blood 118
73. Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914-924
74. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Chronic myelogenous leukemia v.4.2013. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site
75. O'Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505
76. O'Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401-412
77. Orlandi EM, Rocca B, Pazzano AS, Ghio S (2011) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36:e4-e6
78. Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309-2315
79. Pemmaraju N, Kantarjian HM, Luthra R et al (2011) Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). [abstract 1700]. Blood 118
80. Pene-Dumitrescu T, Smithall TE (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285:21446-21457
81. Philibert L, Carzola C, Peyriere H et al (2011) Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. [abstract 476]. Fundam Clin Pharmacol 25:95
82. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE (2010) Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy in unaffected in patients who develop pleural effusion. Cancer 116:377-386
83. Puttini M, Coluccia AM, Boschelli F et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66:11314-11322
84. Quintás-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619-1630
85. Quintás-Cardama A, Kantarjian H, O'Brien S et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914
86. Quintás-Cardama A, Cortés JE, Kantarjian H (2008) Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 8:S82-S88
87. Quintás-Cardama A, Kantarjian H, Ravandi F et al (2009a) Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115:2482-2490
88. Quintás-Cardama A, De Souza Santos FP, Kantarjian H et al (2009b) Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115:3935-3943
89. Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 120:3898-3905
90. Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861-864
91. Redaelli S, Piazza R, Rostagno R et al (2009) Activity of bosutinib, dasatinib and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469-471
92. Rix U, Hantschel O, Dürnberger G et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 110:4055-4063
93. Saglio G, Dombret H, Rea D et al (2008) Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. [abstract 0880]. Haematologica 93:349
94. Saglio G, Kim DW, Issaragrisil S et al (2010a) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 362:2251-2259
95. Saglio G, Hochhaus A, Goh YT et al (2010b) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 116:3852-3861
96. Saglio G, Hochhaus A, Cortes JE et al (2010c) Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. [abstract 2286]. Blood 116
97. Saglio G, Kantarjian HM, Shah N et al (2012) Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. [abstract 1675]. Blood 120
98. Sano M, Saotome M, Urushida T et al (2012) Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med 51:2337-2340
99. Schiffer CA, Cortes JE, Saglio G et al (2010a) Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. [abstract 358]. Blood 116
100. Schiffer CA, Cortes JE, Saglio G et al (2010b) Lymphocytosis following treatment with dasatinib with response and outcome. [abstract 6553]. J Clin Oncol 28:15s
101. Serpa M, Sanabani SS, Bendit I et al (2010) Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol 4:155-162
102. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
103. Shah NP, Skaggs BJ, Branford S et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562-2569
104. Shah NP, Kantarjian HM, Kim DW et al (2008a) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204-3212
105. Shah NP, Kasap C, Weier C et al (2008b) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14:485-493
106. Shah NP, Kim DW, Kantarjian H et al (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232-240
107. Shah NP, Cortes JE, Schiffer CA et al (2011) Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. [abstract 6512]. J Clin Oncol 29
108. Shah NP, Kantarjian H, Kim DW et al (2012) Six-year follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia receiving dasatinib. [abstract 6506]. J Clin Oncol 30
109. Soverini S, Martinelli G, Colarossi S et al (2006) Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24:e51-e52
110. Soverini S, Martinelli G, Colarossi S (2007a) Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 8:273-274
111. Soverini S, Colarossi S, Gnani A et al (2007b) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92:401-404
112. Soverini S, Gnani A, Colarossi S et al (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114:2168-2171
113. ® (dasatinib) capsules [prescribing information] 2013. Princeton, NJ: Bristol-Myers Squibb Company
114. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541
115. Tasigna (nilotinib) capsules [prescribing information] 2013 East Hanover, NJ: Novartis Pharmaceuticals Corporation
116. Tokarski JS, Newitt JA, Chang CY et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790-5797
117. Vajpai N, Strauss A, Fendrich G et al (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 283:18292-18302
118. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure - response analysis of a Phase III study. Clin Pharmacol 5:85-97
119. Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129-141
120. White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064-4072
121. Wong S, Witte ON (2004) The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22:247-306
122. Zhou T, Commodore L, Huang WS et al (2011) Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1-11